TET2 and cancer: This study also established a correlation between TET2 status and myeloid malignancy‐related death, with approximately 33% (21/62) of TET2−/− mice dying before 1 year of age with death directly linked to myeloid malignancy, compared to only 8% (5/66) of TET2+/− mice.